SEC Form 4	
------------	--

(Last)

(First)

29 NEWBURY STREET, 3RD FLOOR

(Middle)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

	hours per response:							
2	eporting Person(s) to Issuer							

	tion 1(b).	iue. See		File							ities Exchang ompany Act c		f 1934			nours	per response:	0.5
						r Section 30(h) of the Investment Company Act of 1940 Issuer Name and Ticker or Trading Symbol Instantion Inc. [BLUE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
					. Date of Earliest Transaction (Month/Day/Year) 11/10/2014								Officer (give title Other (specify below) below)					
(Street) BOSTON	N M	(02116		- 4. li							6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person				son		
(City)	(S	tate) ((Zip)															
			le I - N						1	l, Di	sposed of			-				
1. Title of S	Security (Ins	tr. 3)		Date	ransaction e nth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a			and 5) Secu Bene Own Repo		icially d Following rted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) o (D)			(Instr.	action(s) 3 and 4)		
Common				01/10/		_			S		25,000	D		21.98 ⁽¹⁾	· ·	288,974	D ⁽²⁾	
Common				01/13/	-	_			S		45,000	D		21.8 ⁽³⁾	<u> </u>	243,974	D ⁽²⁾	
Common	Stock			01/14/					S	<u> </u>	270,000	D		21.91 ⁽⁴⁾		973,974	D ⁽²⁾	
		lá	able II ·								osed of, o				wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date, Day/Year)	4. Transa Code 8)		of	iired r osed) r. 3, 4	Expirat	Exercisable and ion Date (Day/Year) Day/Year) Condentifies Derivative Security (Instr. and 4)			Derivative d Security S (Instr. 5) B r. 3 F R T		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er				
		Reporting Person [*]	LP															
(Last) 29 NEW	BURY STE	(First) REET, 3RD FLO	-	ddle)														
(Street) BOSTON	4	МА	02	116														
(City)		(State)	(Zij	D)														
		Reporting Person [*] tures GP, L.P.																
(Last) 29 NEW	BURY STI	(First) REET, 3RD FLO		ddle)														
(Street) BOSTON	1	МА	02	116														
(City)		(State)	(Zij	0)														
1. Name an TRV G		Reporting Person*				_												

(Street) BOSTON	МА	02116
(City)	(State)	(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.75 to \$22.4125, inclusive. Each Reporting Person undertakes to provide to bluebird bio Inc., any security holder of bluebird bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC") and, as such, each of TRV GP and TRV GP LLC exercises shared voting and investment power over the shares held of record by TRV. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.75 to \$21.93, inclusive. Each Reporting Person undertakes to provide to bluebird bio Inc., any security holder of bluebird bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.75 to \$22.07, inclusive. Each Reporting Person undertakes to provide to bluebird bio Inc., any security holder of bluebird bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Kevin Gillis, ChiefFinancial Officer of TRV GP,LLC, general partner of ThirdRock Ventures GP, L.P.,general partner of Third RockVentures, L.P./s/ Kevin Gillis, ChiefFinancial Officer of TRV GP,LLC, general partner of ThirdRock Ventures GP, L.P.

<u>/s/ Kevin Gillis, Chief</u> <u>Financial Officer of TRV GP</u>, <u>01/14/2014</u> <u>LLC</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.